Cardiac Science and Inovise Medical Announce Strategic Alliance; Technology Partnership Promises Immediate Diagnosis of Common Heart Ailments.

Business Editors & Health/Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--April 12, 2001

Cardiac Science Inc. (Nasdaq:DFIB) and privately held Inovise Medical of Newberg, Ore., today announced a strategic alliance which will combine their proprietary technology in the development of cardiac monitoring products.

In addition, Cardiac Science will invest $1 million in Inovise Medical and has obtained a license to Inovise's proprietary software algorithm technology.

Cardiac Science intends to integrate Inovise's Cardiovise(TM) software algorithm technology into its Powerheart(R) monitor- defibrillator, as well as Cardiac Science's new Cardiac Rhythm Module, designed for use with standard patient monitors, anticipated to be released to the market later this year.

"The integration of Cardiovise technology will expand the capability of our fully automatic defibrillation and monitoring products by providing instant detection of the most common types of cardiac abnormalities," said Raymond W. Cohen, president and chief executive officer of Cardiac Science.

"We believe this capability will be particularly useful for patients arriving in the Emergency Room with chest pain. For example, once attached to our Powerheart, a patient will not only be protected against suffering a cardiac arrest, but physicians can also utilize the Cardiovise capability to quickly and inexpensively detect whether or not there's a problem."

Cardiac Science's unique monitor-defibrillator products are designed to prevent patient complications caused by delayed defibrillation and increase patient survival from cardiac arrest.

The product is prophylactically attached to cardiac patients via proprietary disposable defibrillator electrodes to assure that, should patients suffer a sudden life-threatening heart rhythm, they are defibrillated within seconds and without the intervention of hospital staff.

Inovise's Cardiovise software algorithm technology aids in diagnosing heart attacks and many common cardiac abnormalities by analyzing both sound and electrocardiogram information from the heart captured via proprietary disposable patient electrode sensors.

"This alliance will accelerate the adoption of our technology for the care of cardiac patients," said Patti White, president and chief executive officer of Inovise. "The combination of our collective technologies will be a powerful weapon in the fight against heart disease and premature death."

About Cardiac Science

Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary software that monitors a patient's cardiac activity, instantly detects the onset of a life-threatening heart rhythm and automatically delivers defibrillation without human intervention.

The company's proprietary technology has multiple applications, including use in external and wearable defibrillators and with standard patient monitors widely used in hospitals throughout the world. The growth of the company's installed base of devices provides a potential recurring revenue stream from the sale of proprietary disposable defibrillator electrodes.

Cardiac Science began marketing its first commercial product, the Powerheart(R) in the United States in early 2000. For more information, visit www.cardiacscience.com.

About Inovise Medical

Inovise Medical was founded in 1997 by former members of Hewlett-Packard's Diagnostic Cardiology Division's management and technical team. The privately owned company specializes in low-cost, non-invasive, technology-based medical solutions that promise physicians advanced information that will potentially save and extend lives, as well as reduce health-care costs.

Inovise's Cardiovise Cardiac Diagnostic System, the company's latest product, is the first breakthrough in low-cost cardiac diagnosis in more than 25 years and provides physicians with capabilities that are today either unattainable or accessible only through expensive (and often invasive) tests.

The Cardiovise System is comprised of disposable smart electrode sensors that capture both sound and ECG information from the heart and advanced algorithm software that analyzes this information. The findings are presented in a graphic format that is useful to physicians and patients. For more information, visit www.cardiovise.com.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward-looking statements, including statements regarding the life-saving potential of Cardiac Science's technology, the market release of the ADM known as the Cardiac Rhythm Module, Cardiac Science's ability and intension to integrate Inovise's Cardiovise software algorithm technology into its Powerheart and Cardiac Rhythm Module and the anticipated benefits of such integration. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various known and unknown factors including, without limitation, future economic, competitive, regulatory and market conditions, future business decisions, market acceptance of Cardiac Science's products and those factors discussed in Cardiac Science's Form 10-K for the year ending Dec. 31, 2000, and in other documents filed by the company with the Securities and Exchange Commission. In light of the significant uncertainties inherent in such forward-looking statements, the inclusion of such statements should not be regarded as a representation by Cardiac Science's or any other person that Cardiac Science's objectives and plans will be achieved. Words such as "believes," "anticipates," "expects," "intends," "may" and similar expressions are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Cardiac Science undertakes no obligation to revise any of these forward- looking statements, and such statements should not be relied upon by investors when making an investment decision.